Last reviewed · How we verify

NCT03690765

Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Completed Last updated 28 December 2021
What this trial tests

trial testing Duphaston® (Dydrogesterone) in Endometriosis in 350 participants. Completed in 29 May 2020.

Timeline
27 September 2018
Primary endpoint
10 November 2019
29 May 2020

Quick facts

Lead sponsorAbbott
StatusCompleted
Study typeOBSERVATIONAL
Enrollment350
Start date27 September 2018
Primary completion10 November 2019
Estimated completion29 May 2020
Sites21 locations across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Abbott — full company profile →

Who can join

Adults 18 to 45, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A non-interventional, observational program to assess the effects of dydrogesterone (Duphaston®) 6-months-administration in patients with confirmed endometriosis in a post-marketing setting in the Russian Federation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study.
    Sukhikh GT, Adamyan LV, Dubrovina SO, Baranov II, et al · · 2021 · cited 13× · PMID 34465452 · DOI 10.1016/j.fertnstert.2021.07.1194

Verify or expand the search:

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other Abbott trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03690765.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing